Ian Pavord

68.5k total citations · 23 hit papers
608 papers, 35.3k citations indexed

About

Ian Pavord is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ian Pavord has authored 608 papers receiving a total of 35.3k indexed citations (citations by other indexed papers that have themselves been cited), including 506 papers in Physiology, 395 papers in Pulmonary and Respiratory Medicine and 74 papers in Surgery. Recurrent topics in Ian Pavord's work include Asthma and respiratory diseases (491 papers), Respiratory and Cough-Related Research (277 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (148 papers). Ian Pavord is often cited by papers focused on Asthma and respiratory diseases (491 papers), Respiratory and Cough-Related Research (277 papers) and Chronic Obstructive Pulmonary Disease (COPD) Research (148 papers). Ian Pavord collaborates with scholars based in United Kingdom, United States and Canada. Ian Pavord's co-authors include Christopher E. Brightling, Andrew J. Wardlaw, Peter Bradding, Ruth H. Green, Oliver N. Keene, Héctor Ortega, Debbie Parker, Dominick Shaw, Beverley Hargadon and Pranabashis Haldar and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Experimental Medicine.

In The Last Decade

Ian Pavord

580 papers receiving 34.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

2014 1.6k citations Ian Pavord, Guy Brusselle et al. New England Journal of Medicine profile →
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

2012 1.6k citations Ian Pavord, Stephanie Korn et al. profile →
Cluster Analysis and Clinical Asthma Phenotypes

2008 1.4k citations Ian Pavord, Dominick Shaw et al. American Journal of Respiratory and Critical Care Medicine profile →
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

2009 1.4k citations Christopher E. Brightling, Beverley Hargadon et al. New England Journal of Medicine profile →
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial

2002 1.3k citations Christopher E. Brightling, Susan McKenna et al. profile →
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

2014 1.2k citations Elisabeth H. Bel, Ian Pavord et al. New England Journal of Medicine profile →
Mast-Cell Infiltration of Airway Smooth Muscle in Asthma

2002 908 citations Christopher E. Brightling, Andrew J. Wardlaw et al. New England Journal of Medicine profile →
Treatable traits: toward precision medicine of chronic airway diseases

2016 653 citations Àlvar Agustí, Elisabeth H. Bel et al. European Respiratory Journal profile →
Evidence of a Role of Tumor Necrosis Factor α in Refractory Asthma

2006 631 citations Beverley Hargadon, Dominick Shaw et al. New England Journal of Medicine profile →
Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials

2015 504 citations Ian Pavord et al. profile →
Prevalence, pathogenesis, and causes of chronic cough

2008 468 citations Ian Pavord et al. profile →
Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease: A Randomized Placebo-Controlled Trial

2012 422 citations Ian Pavord, Christopher E. Brightling et al. American Journal of Respiratory and Critical Care Medicine profile →
Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study

2015 413 citations David Price, Ian Pavord et al. profile →
Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies

2016 396 citations Christopher E. Brightling, Ian Pavord et al. profile →
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease

2017 384 citations Ian Pavord, Huib A.M. Kerstjens et al. New England Journal of Medicine profile →
Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma

2019 266 citations Richard Beasley, Helen K. Reddel et al. New England Journal of Medicine profile →
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma

2021 258 citations Michael E. Wechsler, Ian Pavord et al. New England Journal of Medicine profile →
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

2022 178 citations Ian Pavord et al. profile →
Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study

2021 169 citations Ian Pavord et al. profile →
Asthma remission: what is it and how can it be achieved?

2022 151 citations Ian Pavord, Peter G. Gibson et al. European Respiratory Journal profile →
Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype

2024 47 citations David J. Jackson, Michael E. Wechsler et al. New England Journal of Medicine profile →
The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma

2024 45 citations Richard Russell, Louis‐Philippe Boulet et al. European Respiratory Journal profile →
Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype

2025 22 citations Alberto Papi, Stephanie Korn et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Ian Pavord

Since Specialization

Citations

This map shows the geographic impact of Ian Pavord's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian Pavord with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian Pavord more than expected).

Fields of papers citing papers by Ian Pavord

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ian Pavord. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian Pavord. The network helps show where Ian Pavord may publish in the future.

Co-authorship network of co-authors of Ian Pavord

This figure shows the co-authorship network connecting the top 25 collaborators of Ian Pavord. A scholar is included among the top collaborators of Ian Pavord based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ian Pavord. Ian Pavord is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAIN 2025 ·Advances in Therapy ·(unknown), Ian Pavord, (unknown), (unknown), Steven A. Gould, (unknown), (unknown), (unknown), (unknown), Stephen G. Noorduyn, (unknown), Stephen Weng, Njira Lugogo	0
2	Reduction in the Use of Rescue Medication for Asthma Symptom Relief With Rilzabrutinib: Results from a Phase 2 Study 2025 ·American Journal of Respiratory and Critical Care Medicine ·William W. Busse, (unknown), Ian Pavord, Michael E. Wechsler, Tianshu Liu, Jessica Gereige, Leda Mannent, Renata Martincova	1
3	TREETOP Study: A Novel Lung Function Technique for the Early Detection of Chronic Obstructive Pulmonary Disease 2025 ·American Journal of Respiratory and Critical Care Medicine ·Nick Smith, (unknown), (unknown), (unknown), John M. Luiz, (unknown), Haonan Xu, Graham Richmond, Robin Fox, Helen Ashdown, Grant A. D. Ritchie, Peter A. Robbins, Ian Pavord, Nick P. Talbot, Nayia Petousi	0
4	The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma breakdown → 2024 ·European Respiratory Journal ·Richard Russell, Louis‐Philippe Boulet, Christopher E. Brightling, Ian Pavord, Celeste Porsbjerg, (unknown), Asger Sverrild	45
5	Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma 2024 ·Journal of Allergy and Clinical Immunology ·Leonard B. Bacharier, Ian Pavord, Jorge Máspero, Daniel J. Jackson, Alessandro Fiocchi, (unknown), Juby A. Jacob‐Nara, Yamo Deniz, Elizabeth Laws, Leda Mannent, Nikhil Amin, Bolanle Akinlade, Heribert Staudinger, David J. Lederer, Megan Hardin	23
6	Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma 2024 ·Journal of Allergy and Clinical Immunology ·Imran Howell, Freda Yang, (unknown), Jennifer Cane, Emanuele Marchi, Adnan Azim, John Busby, P. Jane McDowell, Sarah Diver, Catherine Borg, Liam G. Heaney, Ian Pavord, Christopher E. Brightling, Rekha Chaudhuri, Timothy Hinks	2
7	Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics 2024 ·The Journal of Allergy and Clinical Immunology In Practice ·Arnaud Bourdin, Guy Brusselle, Simon Couillard, Merritt L. Fajt, Liam G. Heaney, Elliot Israel, P. Jane McDowell, Andrew Menzies‐Gow, Neil Martin, Patrick Mitchell, Nayia Petousi, Santiago Quirce, Florence Schleich, Ian Pavord	24
8	Baseline Characteristics and ICS/LAMA/LABA Response in Asthma: Analyses From the CAPTAIN Study 2024 ·The Journal of Allergy and Clinical Immunology In Practice ·Louis‐Philippe Boulet, Carl Abbott, Guy Brusselle, (unknown), John Oppenheimer, Ian Pavord, Emílio Pizzichini, Hironori Sagara, (unknown), Michael E. Wechsler, Peter G. Gibson	2
9	Biologics in Asthma 2024 ·Immunology and Allergy Clinics of North America ·(unknown), Ian Pavord	2
10	IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma 2024 ·Mucosal Immunology ·Jian Luo, Wentao Chen, Wei Liu, Shan Jiang, (unknown), Rahul Shrimanker, Gareth Hynes, Paul Klenerman, Ian Pavord, Luzheng Xue	12
11	Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype breakdown → 2024 ·New England Journal of Medicine ·David J. Jackson, Michael E. Wechsler, Daniel J. Jackson, David I. Bernstein, Stephanie Korn, Paul Pfeffer, Ruchong Chen, Junpei Saito, (unknown), (unknown), Loretta Jacques, (unknown), Stein Schalkwijk, Douglas G. Smith, Peter Howarth, Ian Pavord	47
12	Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthma 2023 ·Respiratory Medicine ·Jorge Máspero, Shirin Shafazand, Jeremy Cole, Ian Pavord, William W. Busse, Jérôme Msihid, (unknown), Xavier Soler, Amr Radwan, Asif Khan, (unknown), Juby A. Jacob‐Nara	2
13	Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort 2021 ·European Respiratory Journal ·Helen K. Reddel, Jørgen Vestbo, Àlvar Agustí, Gary P. Anderson, Aruna T. Bansal, Richard Beasley, Elisabeth H. Bel, Christer Janson, Barry J. Make, Ian Pavord, David Price, Eleni Rapsomaniki, Niklas Karlsson, Donna K. Finch, Javier Nuevo, (unknown), Marianna Alacqua, Rod Hughes, Hana Müllerová, Maria Gerhardsson de Verdier, (unknown)	44
14	CAPTAIN STUDY: EFFECT OF BASELINE LUNG FUNCTION ON RESPONSE TO TRIPLE THERAPY IN PATIENTS WITH ASTHMA INADEQUATELY CONTROLLED ON INHALED CORTICOSTEROID/LONG-ACTING BETA2-AGONIST THERAPY 2020 ·CHEST Journal ·Robert A. Nathan, Louis‐Philippe Boulet, Huib A.M. Kerstjens, Alberto Papi, Ian Pavord, Nicola A. Hanania, John Oppenheimer, (unknown), Mark Liu, Steven P. Weinstein, David M. Mannino, Guy Peachey, (unknown), Neal Sule, Andrew Fowler, (unknown), Edward Kerwin	0
15	Prostaglandin D2 type 2 receptor antagonism reduces airway smooth muscle mass in asthma: mechanistic insights from in vitro and computational models 2019 ·The Novartis Repository (Novartis) ·(unknown), Himanshu Kaul, Rachid Berair, Sherif Gonem, Amisha Singapuri, Amanda Sutcliffe, Latifa Chachi, Michael Biddle, Davinder Kaur, Michelle Bourne, Ian Pavord, Andrew J. Wardlaw, Salman Siddiqui, Bindi S. Brook, R. H. Smallwood, Christopher E. Brightling	0
16	A new approach to the classification and management of airways diseases: identification of treatable traits 2017 ·Clinical Science ·Rahul Shrimanker, (unknown), Ian Pavord	28
17	Efficacy and safety of AZD5069, a CXCR2 antagonist, in adult bronchiectasis 2013 ·European Respiratory Journal ·Ian Pavord, Anthony De Soyza, J.S. Elborn, David L. Smith, Heather Wray, Margareta Puu, B. Larsson, Robert A. Stockley	7
18	Reducing asthma exacerbations in practise: An observational study 2004 ·Thorax ·Dominick Shaw, M A Berry, Christopher E. Brightling, Andrew J. Wardlaw, Ian Pavord, (unknown)	1
19	Observational study of the natural history of eosinophilic bronchitis 2003 ·Thorax ·M A Berry, Christopher E. Brightling, Beverley Hargadon, Susan McKenna, Andrew J. Wardlaw, Ian Pavord	2
20	The airway effects of stopping regular oral theophylline in patients with asthma 1998 ·British Journal of Clinical Pharmacology ·(unknown), Jo Thompson Coon, Ian Pavord, P Wilding, AE Tattersfield	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact